Cancer and Cell Therapy · global
CAR-T Therapy Targeting B7-H3 and IL-8 in Colorectal Cancer Gets FDA Clearance for Human Trials
A University of Colorado team aims to address both a tumor recognition marker and cancer-promoting signals, seeking a new option for patients whose standard treatments have failed. The trial will first assess safety, while projected launch dates differ. No human efficacy results are available yet.
As standard treatments gradually stop working, patients with advanced colorectal cancer need new options to continue treatment. On September 10, the University of Colorado Anschutz Medical Campus (CU Anschutz) announced that an experimental CAR-T cell therapy developed by its researchers had received clearance from the U.S. Food and Drug Administration (FDA) for human trials, preparing to explore the potential of modified immune cells to fight this type of solid tumor. This clearance opens the way for clinical testing; it does not mean the therapy has been approved for routine treatment.
According to the university's announcement, the trial will include adults with advanced colorectal cancer who have exhausted standard treatment options, as well as children with solid cancers, and will be led by oncologist Christopher Lieu. The initial focus is to establish safety and assess whether these cells can attack cancer in the human body. The information currently available does not include efficacy data from participants.
CAR-T therapy involves removing a patient's T cells, genetically modifying them to recognize cancer, and then expanding the cells before infusing them back into the body. This strategy has achieved results in some leukemias and lymphomas, but solid tumors are more difficult to treat. One challenge is finding a target that is sufficiently common on cancer cells yet as rare as possible on healthy tissue, allowing room to attack tumors while protecting normal tissue.
This study incorporates B7-H3 and IL-8 into a single treatment strategy. The former is a protein found in many colorectal tumors, while the latter is involved in signals that promote tumor growth, inflammation, and spread. The team hopes that addressing both components will improve the chances of engineered T cells overcoming tumor defenses. However, public reports have not detailed the full cell engineering design, so the description of “dual targeting” alone does not establish that both are recognized or inhibited in the same way.
Bringing the concept into human trials also requires reliable manufacturing capacity. The cells will be prepared at the campus's Gates Biomanufacturing Facility. A follow-up university report on September 21 identified the on-campus manufacturing facility and philanthropic funding as important factors in advancing the research into clinical testing. The same report mentioned other patients participating in a pharmaceutical company-sponsored CAR-T trial targeting GCC. That is a separate study and cannot serve as human evidence for this B7-H3 and IL-8 therapy.
Accounts still differ on when the trial will open. The university's reports on September 10 and 21 both projected a December launch, while the Colorectal Cancer Alliance wrote on September 22 that it was expected to open in January or February 2027. These are all projected timelines, and the available sources are insufficient to confirm when enrollment will actually begin.
The significance of this research lies in advancing a new approach to solid tumors to a stage where it can be tested using human data. The relative prevalence of B7-H3 in tumors provides a rationale for studying broader applicability. However, whether the therapy can safely recognize tumors, produce responses, and sustain those responses—and for how long—must still be answered by clinical trials.